Pharmaceutical Grade Ceritinib Powder Anti-Cancer Ceritinib

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Ceritinib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Ceritinib
• CAS Number: 1032900-25-6
• Molecular Formula: C28h36cln5o3s
• Molecular Weight: 558.14 G/Mol
• Flow Rate: 1.0 Ml/Min
• Detection Wavelength: 260 Nm
• Column Temperature: 30°c
• Injection Volume: 10 μl
• Appearance: White to off-White Powder
• Identification: Retention Time Matches Reference Standard
• Water Content (Kf): ≤0.5% W/W
• Residual Solvents (Gc): Meets Ich Q3c Limits
• Tailing Factor: ≤2.0
• Theoretical Plates: ≥2000
• Retention Time: ~6-8 Min
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS
• Origin: Xian
• Production Capacity: 4500 Kg/Month

Product Description

Pharmaceutical Grade Ceritinib powder Anti-Cancer Ceritinib

Product Description

Product Details

Product Name	Ceritinib
Apperance	White to off-white powder
CAS	1032900-25-6
MF	C28H36ClN5O3S
MW	558.14 g/mol

Ceritinib is a highly efficient and selective small molecule ALK (anaplastic lymphoma kinase) inhibitor primarily used for the treatment of ALK positive non-small cell lung cancer (NSCLC). Its chemical structure has been optimized to effectively penetrate the blood-brain barrier and exhibit significant activity towards central nervous system metastases. Ceritinib inhibits the abnormal activation of ALK protein, blocking the proliferation and survival signals of tumor cells. This drug has shown good anti-tumor effects in clinical practice, especially for patients who are resistant or intolerant to crizotinib, and is one of the important breakthroughs in the field of targeted therapy.

Application&Function

Ceritinib is mainly used to treat advanced or metastatic non-small cell lung cancer (NSCLC) with positive ALK gene rearrangement. Its core mechanism of action is to specifically inhibit ALK kinase activity, block downstream signaling pathways such as PI3K/AKT and MAPK, thereby inhibiting the growth, proliferation, and metastasis of tumor cells. Clinical studies have shown that Ceritinib still has significant therapeutic effects on patients resistant to crizotinib and can effectively control brain metastases. Common side effects include gastrointestinal reactions and liver dysfunction, but overall tolerability is controllable. This drug provides an important second-line treatment option for ALK positive lung cancer patients, significantly prolonging progression free survival (PFS).

Specification

ABOUT US